FDA Logo links to FDA home page
Center for Drug Evaluation and Research, U.S. Food and Drug AdministrationU.S. Food and Drug AdministrationCenter for Drug Evaluation and Research
  HHS Logo links to Department of Health and Human Services website

FDA Home Page | CDER Home Page | CDER Site Info | Contact CDER | What's New @ CDER

horizonal rule
CDER Home About CDER Drug Information Regulatory Guidance CDER Calendar Specific Audiences CDER Archives
 
Powered by Google
 

AASLD-FDA-NIH-PhRMA*- Hepatotoxicity Special Interest Group Meeting
2008 Presentations

 

Paul B. Watkins, M.D.
Watkins' Opening Remarks [PDF] PDF document

Biography

Paul Watkins received his M.D. degree from Cornell Medical School in 1979.  He completed his internship and residency in Internal Medicine at the New York Hospital – Cornell Medical Center, and then completed a Gastroenterology Fellowship at the Medical College of Virginia.  He joined the faculty at the University of Michigan in 1986 as an Assistant Professor.  He became Director of the General Clinical Research Center (GCRC) at the University of Michigan in 1992.  He was promoted to the rank of Professor of Medicine and Professor of Pharmacology in 1997.  He remained Director of the GCRC at University of Michigan until he was recruited to the University of North Carolina in July of 1999.  There he became the Verne S. Caviness Distinguished Professor of Medicine and Professor of Pharmacotherapy, and assumed the role as Director of the GCRC.  Dr. Watkins’ area of research has been Drug Metabolism and Disposition.  He has had continual support from the NIH for his research since 1986, and in 1998 received an NIH MERIT Award.  He has received several honors for his research, including the Therapeutic Frontiers’ Lecture Award from the American College of Clinical Pharmacy in 1998. He is one of the top 250 most cited authors in the field of Pharmacology for the two decades ending 2004 according to ISIhighlycited.com.  He has served on many national committees, including Toxicology I Study Section of the National Institutes of Health and the Committee for the Comparative Toxicity of Naturally Occurring Carcinogens at the National Academy of Sciences

Dr. Watkins’ clinical area of interest is Drug-Induced Liver Injury, and he has consulted widely for industry and governmental agencies in this area.    He is the current Chair of the Steering Committee for the Drug Induced Liver Injury Network (DILIN) funded by the National Institute for Diabetes Digestive and Kidney Diseases.

 

to top arrow Back to Top     back arrow Back to Presentations

PDF document PDF requires the free Adobe Acrobat Reader

Date created: April 29, 2008

horizonal rule